Ocular HSV: A leading cause of blindness1,2
Annually in the United States, there are:
~24,000
new cases
of ocular HSV
~34,000
CASES OF
RECURRENCE
~500,000
people WITH
HSV-related
ocular disease
Herpes Simplex Virus Dendritic Epithelial Keratitis
Christopher Rapuano, MD and Joseph Shovlin, OD, FAAO provide their insights on and tips for treating this common form of HSV.
Read now >>
Herpes Simplex Virus Dendritic Epithelial Keratitis: Diagnosis and Management
Marguerite McDonald, MD, FACS provides insight into diagnosing dendritic epithelial keratitis caused by the herpes simplex virus, and management of this type of ocular infection.
Read now >>
Accessing ZIRGAN
See if your patients are covered with Bausch + Lomb’s formulary tool.
Check our formulary toolIndication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
Click here for full Prescribing Information for ZIRGAN.
ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.
References: 1. Wang JC, Ritterband DC. Herpes simplex virus (HSV) keratitis. Medscape Website. https://emedicine.medscape.com/article/1194268-overview#a6. Updated November 3, 2017. Accessed August 16, 2018. 2. Young RC, Hodge DO, Liesegang TJ, Baratz KH. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976–2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol. 2010;128(9):1178–1183.
Indication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
Click here for full Prescribing Information for ZIRGAN.
ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.
THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below:
THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below: